Neoadjuvant therapy for resectable pancreatic adenocarcinoma: An interim report of a prospective randomized study.

e14604 Background: We compare neoadjuvant chemoradiation therapy plus surgery versus surgery alone in patients with resectable pancreatic adenocarcinoma (RPA) in a prospective, controlled, randomized study. The primary end-point was to evaluate the R0 resection rate in the two groups and secondary was safety/efficacy of neoadjuvant therapy, postoperative mortality, morbidity, lymph node-ratio and pTNM stage. Methods: Patients with RPA were randomized to receive either neoadjuvant therapy plus surgery (group A) or surgery alone (group B). In group A, patients received gemcitabine (1,000 mg/m2) on days 1,8 every 21, followed by radiation therapy (45 Gy plus boost of 9 Gy) plus gemcitabine 50 mg/m2 biweekly, for 6 weeks. A CT scan restaging was performed before surgery. Results: From March 2007 we enrolled 19 consecutive patients (9 male and 8 female). Seventeen among the eligible patients 7 (41%) were randomized in group A and 10 (59%) in group B. After neoadjuvant therapy one patient (14.3%) had a progress...